(BLCM) - Earnings & Price History

BLCM: - 9.77, $326.27M, 0.35 (3.72%)

Sector: Healthcare - Industry: Biotechnology

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The companys preclinical product candidates include BPX-601, a chimeric antigen receptor (CAR-T) product candidate for treating solid tumors expressing the prostate stem cell antigen; BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma; and BPX-401, a CAR-T product candidate for the treatment of hematological cancers that express the CD19 antigen. The company h

Past BLCM reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-13AMC-0.7113.4114.0913.4712.7213.63-4.40%-0.45%-4.83%906.86K
2016-11-09AMC-0.6320.4919.2819.2319.1320.95-0.26%▲6.55%6.28%558.32K
2016-11-08AMC-0.6319.2817.7318.4818.3819.984.23%▲4.33%8.74%608.19K
2016-11-07AMC-0.6317.7317.7517.517.2918.15-1.41%▲1.31%-0.11%245.89K
2016-08-08AMC-0.5719.8817.0518.517.8519.998.50%7.46%16.60%758.81K
2016-05-09AMC-0.519.369.419.48.789.43-0.11%-0.43%-0.53%304.94K
2016-03-14AMC-0.448.0910.039.58.019.77-5.28%-14.84%-19.34%1.47M
2015-08-13AMC-0.4918.4817.8317.6316.6718.8-1.12%4.82%3.65%342.72K
2015-03-11AMC-0.3723.5223.3622.9622.5524.49-1.71%2.44%0.68%240.18K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades